Zobrazeno 1 - 10
of 118
pro vyhledávání: '"63"'
Autor:
Nicolay V. Litviakov, Elena M. Slonimskaya, Polina V. Kazantseva, M.K. Ibragimova, Matvey M. Tsyganov
Publikováno v:
Journal of Clinical Oncology. 37:e14655-e14655
e14655 Background: Neoadjuvant chemotherapy (NAС) is one of the treatment options for breast cancer (BC). However, chemotherapy is known can cause intratumoral changes that increase the risk of metastasis. We have previously found that the appearanc
Autor:
Verena Sagaster, Lea Roxana Ionce, Yelena Devyatko, Marie-Bernadette Aretin, Ruth Exner, Maximilian Marhold, Kerstin Wimmer, Alexandra Christ, Florian Fitzal, Guenther G. Steger
Publikováno v:
Journal of Clinical Oncology. 37:e12114-e12114
e12114 Background: Her2-positive (Her2pos) breast cancer (BCa) is the second most lethal subtype of BCa. The treatment of Her2-positive BCa was revolutionized due to the dual use of trastuzumab and pertuzumab (T+P) in recent years both in the neoadju
Autor:
Amit Rauthan, S.P. Somashekhar
Publikováno v:
Journal of Clinical Oncology. 31:e11510-e11510
e11510 Background: Sentinel node biopsy has emerged as the standard of care in clinically node negative breast cancer (cT1,T2 N0). In cases where sentinel node is negative, ALND can be avoided. In nearly 30-50% cases, the sentinel lymph nodes is the
Autor:
Kazuaki Nakashima, Hikaru Fujioka, Hiroaki Tohyama, Masahiro Ito, Yasuhiro Nagata, Shigeto Maeda, Yukiko Tokai, Yukio Kamohara
Publikováno v:
Journal of Clinical Oncology. 31:e11605-e11605
e11605 Background: Hormone therapy is recommended for treating patients with luminal A type early breast cancer by the International Conference in St. Gallen, 2011. However, precisely which neoadjuvant therapeutic strategies are optimal for such pati
Autor:
Dana Zakalik, Ishmael Jaiyesimi, Lindsay Dohany, Mohammad Muhsin Chisti, Seerin Viviane Shatavi
Publikováno v:
Journal of Clinical Oncology. 31:1541-1541
1541 Background: Worldwide ethnic variations in the distribution of BRCA1 and BRCA2 mutations of breast cancer patients have been recently recognized. This has led to investigations of the epidemiology, genetics and clinical characteristics of BRCA p
Autor:
Lei Han, Kathleen I. Pritchard, Judy-Anne W. Chapman, Timothy J. Whelan, Wendy R. Parulekar, Lois E. Shepherd, Paul E. Goss, Abdullah Altwairgi
Publikováno v:
Journal of Clinical Oncology. 30:500-500
500 Notice of Retraction: "Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27." Abstract 500, published in the 2012 Annual Meeting Proceedings P
Autor:
Silvia Munoz, Joan Brunet, Rafael Marcos, L. Vilardell, Neus Baste, Angel Izquierdo, Maria Buxó, Núria Sala, Maria Pilar Barretina Ginesta, M. Beltran
Publikováno v:
Journal of Clinical Oncology. 30:1588-1588
1588 Background: Excess of risk of several second primary malignancies after treatment for breast cancer (BC) has been reported. This risk can be related with shared risk factors, cancer susceptibility genes or prior treatments received. Hormonal fac
Autor:
L. Franco, D. A. Yardley, M. Lange, N. W. Peacock, E. Vazquez, John D. Hainsworth, Mythili Shastry, E. Raefsky, R. C. Inhorn, Victor M. Priego
Publikováno v:
Journal of Clinical Oncology. 27:e11509-e11509
e11509 Background: Docetaxel/cyclophosphamide has demonstrated superior disease free and overall survival compared to doxorubicin/cyclophosphamide in the treatment of early stage breast cancer with an acceptable safety profile, with grade (G) 3/4 neu
Autor:
E. K. Dice, Christine M. Schurman, Eva Thomas, S. C. Phan, Vicente Valero, Robert W. Carlson, Edgardo Rivera, Cathie T. Chung
Publikováno v:
Journal of Clinical Oncology. 25:1030-1030
1030 Background: Aromatase inhibitors (AIs) are highly active in postmenopausal women with hormone receptor positive breast cancer. However, the AIs do not suppress ovarian estrogen synthesis and are not effective in premenopausal women. This phase I
Autor:
M.M.A. Tilanus-Linthorst, C. M. G. Crepin, J.G.M. Klijn, Marian B. E. Menke-Pluymers, C.C.M. Bartels, Hanne Meijers-Heijboer, C.T.M. Brekelmans, A.N. van Geel, Caroline Seynaeve
Publikováno v:
Journal of Clinical Oncology. 22:9502-9502
9502 Background: Previously we reported on the efficacy of prophylactic bilateral total mastectomy (PM) in the first prospective study of 139 healthy women with a pathogenic BRCA1 or BRCA2 mutation (Meijers-Heijboer et al, NEJM 345: 159–164, 2001).